{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T06:14:24Z","timestamp":1794464064094,"version":"4.9.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010091","name":"International Foundation for CDKL5 Research","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100010091","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Institute of Health","award":["U01NS114312"],"award-info":[{"award-number":["U01NS114312"]}]},{"DOI":"10.13039\/501100020265","name":"Stan Perron Charitable Foundation","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100020265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>CDKL5 Deficiency Disorder (CDD) is a rare neurodevelopmental disorder characterised by early onset seizures combined with complex healthcare needs and developmental impairment that influence functional domains including communication. Communication is a high priority domain for families but currently used measures demonstrate floor effects. Emerging disease-modifying trials necessitate the precise and granular measurement of communication to determine drug efficacy. This study evaluated a new measure of communication for CDD called the Communication Inventory Disability \u2013 Observer Reported (CID-OR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      CID-OR was developed using a communication framework for CDD created from qualitative data and informed through evaluation of current measures and consultation with clinical experts. Scores for items describing communicative purpose were derived from ratings of consistency and the mode of delivery. An online survey was administered to parents of people with CDD (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009184) recruited from the International CDKL5 Clinical Research Network. Most caregivers (96%) completed the Communication and Symbolic Behavior Scales - Developmental Profile Infant Toddler Checklist (CSBS\u2013DP ITC). A confirmatory factor analysis was conducted. Test-retest reliability and comparison of known groups were assessed using intraclass correlation coefficients and linear regression, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The median age of people with CDD was 9.8 (1\u201343) years. A single factor model was evaluated. For 34 items, item loadings were satisfactory. For the scale, internal consistency and goodness-of-fit statistics were satisfactory, except for the Root Mean Square Error of Approximation statistic. The distribution of CID-OR scores was less right skewed than for CSBS-DP ITC scores although there was a high correlation between CID-OR and CSBS scores (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.89). Test-retest reliability was high (ICC 0.966).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Preliminary analysis suggests that CID-OR is a reliable and valid measure of communication in CDD. This new tool has strong potential to measure responsiveness to interventions in CDD and may extend to similar developmental and epileptic encephalopathy conditions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41687-025-00977-z","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T08:09:34Z","timestamp":1765267774000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Development and initial validation of the Communication Inventory Disability \u2013 Observer Reported (CID-OR): a measure of communication in CDKL5 deficiency disorder"],"prefix":"10.1186","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7358-9037","authenticated-orcid":false,"given":"Jenny","family":"Downs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Keeley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Jacoby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Benson-Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Pillar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Miele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Leonard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacinta","family":"Saldaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric D.","family":"Marsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim A.","family":"Benke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott T.","family":"Demarest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"key":"977_CR1","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S1474-4422(22)00035-7","volume":"21","author":"H Leonard","year":"2022","unstructured":"Leonard H, Downs J, Benke TA, Swanson L, Olson H, Demarest S (2022) CDKL5 deficiency disorder: clinical features, diagnosis, and management. Lancet Neurol 21:563\u2013576","journal-title":"Lancet Neurol"},{"key":"977_CR2","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1866-1955-7-2","volume":"7","author":"S Fehr","year":"2015","unstructured":"Fehr S, Leonard H, Ho G, Williams S, de Klerk N, Forbes D, Christodoulou J, Downs J (2015) There is variability in the attainment of developmental milestones in the CDKL5 disorder. J Neurodev Disord 7:2","journal-title":"J Neurodev Disord"},{"key":"977_CR3","doi-asserted-by":"crossref","unstructured":"Mangatt M, Wong K, Anderson B, Epstein A, Hodgetts S, Leonard H, Downs J (2016) Prevalence and onset of comorbidities in the CDKL5 disorder differ from Rett syndrome. Orphanet J Rare Dis 11","DOI":"10.1186\/s13023-016-0418-y"},{"key":"977_CR4","unstructured":"Mingorance A, Jaksha A, Smart T, Sherriff L, Valentine J (2020) The Voice of the Patient Report: CDKL5 Deficiency Disorder (CDD). Lou Lou Foundation, International Foundation for CDKL5 Research"},{"key":"977_CR5","doi-asserted-by":"crossref","unstructured":"Neul JL, Benke TA, Marsh ED, Suter B, Silveira L, Fu C, Peters SU, Percy AK (2023) Top caregiver concerns in Rett syndrome and related disorders: data from the US natural history study. J Neurodev Disord 15","DOI":"10.1186\/s11689-023-09502-z"},{"key":"977_CR6","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1352\/1944-7558-125.6.434","volume":"125","author":"C DiStefano","year":"2020","unstructured":"DiStefano C, Sadhwani A, Wheeler AC (2020) Comprehensive assessment of individuals with significant levels of intellectual disability: Challenges, Strategies, and future directions. Am J Intellect Dev Disabil 125:434\u2013448","journal-title":"Am J Intellect Dev Disabil"},{"key":"977_CR7","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.rasd.2017.08.002","volume":"41\u201342","author":"LE Miller","year":"2017","unstructured":"Miller LE, Perkins KA, Dai YG, Fein DA (2017) Comparison of parent report and direct assessment of child skills in toddlers. Res Autism Spectr Disord 41\u201342:57\u201365","journal-title":"Res Autism Spectr Disord"},{"key":"977_CR8","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1111\/1460-6984.13100","volume":"59","author":"JM Saldaris","year":"2024","unstructured":"Saldaris JM, Ayalde J, Kankanange S, Keeley J, Leonard H, Jacoby P, Marsh ED, Benke TA, Demarest ST, Downs J (2024) Parent-reported outcome measures evaluating communication in individuals with rare neurodevelopmental disorders: A systematic review. Int J Lang Commun Disord 59:2528\u20132553","journal-title":"Int J Lang Commun Disord"},{"key":"977_CR9","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1352\/1944-7558-128.3.204","volume":"128","author":"CK Zigler","year":"2023","unstructured":"Zigler CK, Lin L, McFatrich M, Lucas N, Gordon KL, Jones HN, Berent A, Panagoulias J, Evans P, Reeve BB (2023) Validation of the Observer-Reported communication ability (ORCA) measure for individuals with Angelman syndrome. Am J Intellect Dev Disabil 128:204\u2013218","journal-title":"Am J Intellect Dev Disabil"},{"key":"977_CR10","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ejpn.2023.07.007","volume":"46","author":"BB Reeve","year":"2023","unstructured":"Reeve BB, Lucas N, Chen D, McFatrich M, Jones HN, Gordon KL, Leiva LZ, Lin L, Coenraads M, von Hehn J et al (2023) Validation of the Observer-Reported communication ability (ORCA) measure for individuals with Rett syndrome. Eur J Paediatr Neurol 46:74\u201381","journal-title":"Eur J Paediatr Neurol"},{"key":"977_CR11","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1044\/1092-4388(2002\/097)","volume":"45","author":"AM Wetherby","year":"2002","unstructured":"Wetherby AM, Allen L, Cleary J, Kublin K, Goldstein H (2002) Validity and reliability of the communication and symbolic behavior scales developmental profile with very young children. J Speech Lang Hear Res 45:1202\u20131218","journal-title":"J Speech Lang Hear Res"},{"key":"977_CR12","volume-title":"Communication and symbolic behavior scales developmental profile (CSBS DP), first normed edition","author":"AM Wetherby","year":"2002","unstructured":"Wetherby AM, Prizant BM (2002) Communication and symbolic behavior scales developmental profile (CSBS DP), first normed edition, 1st edn. Paul H. Brookes Publishing Co., Baltimore","edition":"1"},{"key":"977_CR13","doi-asserted-by":"publisher","first-page":"108586","DOI":"10.1016\/j.yebeh.2022.108586","volume":"128","author":"AT Berg","year":"2022","unstructured":"Berg AT, Kaat AJ, Zelko F, Wilkening G (2022) Rare diseases - rare outcomes: assessing communication abilities for the developmental and epileptic encephalopathies. Epilepsy Behav 128:108586","journal-title":"Epilepsy Behav"},{"key":"977_CR14","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1038\/s41591-023-02398-1","volume":"29","author":"JL Neul","year":"2023","unstructured":"Neul JL, Percy AK, Benke TA, Berry-Kravis E, Glaze M, Marsh DG, Lin ED, Stankovic T, Bishop S, Youakim KM (2023) Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study. Nat Med 29:1468\u20131475","journal-title":"Nat Med"},{"key":"977_CR15","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1007\/s10803-023-06002-w","volume":"54","author":"J Saldaris","year":"2024","unstructured":"Saldaris J, Leonard H, Wong K, Jacoby P, Spence M, Marsh E, Benke TA, Demarest S, Downs J (2024) Validating the communication and symbolic behavior Scales \u2013 Developmental profile Infant-Toddler checklist (CSBS-DP ITC) beyond infancy in the CDKL5 deficiency disorder. J Autism Dev Disord 54:2526\u20132535","journal-title":"J Autism Dev Disord"},{"key":"977_CR16","doi-asserted-by":"publisher","first-page":"e63570","DOI":"10.1002\/ajmg.a.63570","volume":"194","author":"J Keeley","year":"2024","unstructured":"Keeley J, Benson-Goldberg S, Saldaris J, Lariviere J, Leonard H, Marsh ED, Demarest ST, Benke TA, Jacoby P, Downs J (2024) Communication of individuals with CDKL5 deficiency disorder as observed by caregivers: A descriptive qualitative study. Am J Med Genet A 194:e63570","journal-title":"Am J Med Genet A"},{"key":"977_CR17","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1111\/cch.12691","volume":"45","author":"A Epstein","year":"2019","unstructured":"Epstein A, Williams K, Reddihough D, Murphy N, Leonard H, Whitehouse A, Jacoby P, Downs J (2019) Content validation of the quality of life Inventory-Disability. Child Care Health Dev 45:654\u2013659","journal-title":"Child Care Health Dev"},{"key":"977_CR18","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1177\/08830738211019576","volume":"36","author":"J Saldaris","year":"2021","unstructured":"Saldaris J, Weisenberg J, Pestana-Knight E, Marsh ED, Suter B, Rajaraman R, Heidary G, Olson HE, Devinsky O, Price D et al (2021) Content validation of Clinician-Reported items for a severity measure for CDKL5 deficiency disorder. J Child Neurol 36:998\u20131006","journal-title":"J Child Neurol"},{"key":"977_CR19","doi-asserted-by":"publisher","first-page":"107231","DOI":"10.1016\/j.eplepsyres.2023.107231","volume":"197","author":"SI Ziniel","year":"2023","unstructured":"Ziniel SI, Mackie A, Saldaris J, Leonard H, Jacoby P, Marsh ED, Suter B, Pestana-Knight E, Olson HE, Price D et al (2023) The development, content and response process validation of a caregiver-reported severity measure for CDKL5 deficiency disorder. Epilepsy Res 197:107231","journal-title":"Epilepsy Res"},{"key":"977_CR20","doi-asserted-by":"crossref","unstructured":"Keeley J, Saldaris J, Benson-Goldberg S, Lariviere J, Leonard H, Marsh ED, Demarest ST, Benke TA, Jacoby P, Downs J (2025) Content validation of the Communication Inventory Disability-Observer Reported (CID-OR). J Child Neurol 8830738251369138","DOI":"10.1177\/08830738251369138"},{"key":"977_CR21","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1111\/brv.12685","volume":"96","author":"Y Ben Mocha","year":"2021","unstructured":"Ben Mocha Y, Burkart JM (2021) Intentional communication: solving methodological issues to assigning first-order intentional signalling. Biol Rev 96:903\u2013921","journal-title":"Biol Rev"},{"key":"977_CR22","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1044\/1058-0360(2011\/10-0099)","volume":"21","author":"NC Brady","year":"2012","unstructured":"Brady NC, Fleming K, Thiemann-Bourque K, Olswang L, Dowden P, Saunders MD, Marquis J (2012) Development of the communication complexity scale. Am J Speech Lang Pathol 21:16\u201328","journal-title":"Am J Speech Lang Pathol"},{"key":"977_CR23","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1177\/152574010002100202","volume":"21","author":"J Sigafoos","year":"2000","unstructured":"Sigafoos J, Woodyatt G, Keen D, Tait K, Tucker M, Roberts-Pennell D, Pittendreigh N (2000) Identifying potential communicative acts in children with developmental and physical disabilities. Communication Disorders Q 21:77\u201386","journal-title":"Communication Disorders Q"},{"key":"977_CR24","first-page":"319","volume":"3","author":"C Rowland","year":"2010","unstructured":"Rowland C, Fried-Oken M (2010) Communication matrix: A clinical and research assessment tool targeting children with severe communication disorders. J Pediatr Rehabil Med 3:319\u2013329","journal-title":"J Pediatr Rehabil Med"},{"key":"977_CR25","unstructured":"Sparrow SS, Cicchetti DV, Saulnier CA (2016) Vineland Adaptive Behavior Scales. 3rd ed. Pearson"},{"key":"977_CR26","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1007\/s11136-009-9540-9","volume":"18","author":"M Brod","year":"2009","unstructured":"Brod M, Tesler LE, Christensen TL (2009) Qualitative research and content validity: developing best practices based on science and experience. Qual Life Res 18:1263\u20131278","journal-title":"Qual Life Res"},{"key":"977_CR27","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s11136-011-9960-1","volume":"21","author":"CB Terwee","year":"2012","unstructured":"Terwee CB, Mokkink LB, Knol DL, Ostelo RW, Bouter LM, de Vet HC (2012) Rating the methodological quality in systematic reviews of studies on measurement properties: a scoring system for the COSMIN checklist. Qual Life Res 21:651\u2013657","journal-title":"Qual Life Res"},{"key":"977_CR28","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1111\/epi.16285","volume":"60","author":"ST Demarest","year":"2019","unstructured":"Demarest ST, Olson HE, Moss A, Pestana-Knight E, Zhang X, Parikh S, Swanson LC, Riley KD, Bazin GA, Angione K et al (2019) CDKL5 deficiency disorder: relationship between genotype, epilepsy, cortical visual impairment, and development. Epilepsia 60:1733\u20131742","journal-title":"Epilepsia"},{"key":"977_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10705519909540118","volume":"6","author":"L Hu","year":"1999","unstructured":"Hu L, Bentler PM (1999) Cutoff criteria for fit indexes in covariance structure analysis: conventional criteria versus new alternatives. Struct Equation Modeling: Multidisciplinary J 6:1\u201355","journal-title":"Struct Equation Modeling: Multidisciplinary J"},{"key":"977_CR30","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1177\/002224378101800104","volume":"18","author":"C Fornell","year":"1981","unstructured":"Fornell C, Larcker D (1981) Evaluating structural equation models with unobservable variables and measurement error. J Mark Res 18:39\u201350","journal-title":"J Mark Res"},{"key":"977_CR31","first-page":"231","volume":"19","author":"JP Weir","year":"2005","unstructured":"Weir JP (2005) Quantifying test-retest reliability using the intraclass correlation coefficient and the SEM. J Strength Cond Res 19:231\u2013240","journal-title":"J Strength Cond Res"},{"key":"977_CR32","unstructured":"Benke TA, Demarest S, Angione K, Downs J, Leonard H, Saldaris J, Marsh ED, Olson H, Haviland I (2024) CDKL5 Deficiency Disorder. In Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews\u00ae. Seattle (WA): University of Washington, Seattle"},{"key":"977_CR33","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1177\/0049124114543236","volume":"44","author":"DA Kenny","year":"2015","unstructured":"Kenny DA, Kaniskan B, McCoach DB (2015) The performance of RMSEA in models with small degrees of freedom. Sociol Methods Res 44:486\u2013507","journal-title":"Sociol Methods Res"},{"key":"977_CR34","volume-title":"Developmental profile 4 (DP-4)","author":"G Alpern","year":"2019","unstructured":"Alpern G (2019) Developmental profile 4 (DP-4). Western Psychological Services, Los Angeles, CA"},{"key":"977_CR35","unstructured":"Food and Drug Administration (2020) Patient-Focused Drug Development: Collecting Comprehensive and Representative Input. Food and Drug Administration"},{"key":"977_CR36","unstructured":"Food and Drug Administration (2025) Patient-focused drug development: selecting, developing, or modifying fit-for-purpose clinical outcome assessments guidance for industry, Food and Drug Administration staff, and other stakeholders. US Department of Health and Human Services"},{"key":"977_CR37","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1093\/brain\/awz195","volume":"142","author":"JD Symonds","year":"2019","unstructured":"Symonds JD, Zuberi SM, Stewart K, McLellan A, O\u2019Regan M, MacLeod S, Jollands A, Joss S, Kirkpatrick M, Brunklaus A et al (2019) Incidence and phenotypes of childhood-onset genetic epilepsies: a prospective population-based National cohort. Brain 142:2303\u20132318","journal-title":"Brain"},{"key":"977_CR38","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1111\/epi.17547","volume":"64","author":"KL Oliver","year":"2023","unstructured":"Oliver KL, Scheffer IE, Bennett MF, Grinton BE, Bahlo M, Berkovic SF (2023) Genes4Epilepsy: an epilepsy gene resource. Epilepsia 64:1368\u20131375","journal-title":"Epilepsia"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-025-00977-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-025-00977-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-025-00977-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:11:56Z","timestamp":1781622716000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41687-025-00977-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["977"],"URL":"https:\/\/doi.org\/10.1186\/s41687-025-00977-z","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,9]]},"assertion":[{"value":"8 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Internal Review Board at University of Colorado COMIRB 19-2756, with reliance agreements at each clinical site, and University of Western Australia (RA\/4\/20\/6198). The International CDKL5 Clinical Research Network (ICCRN) is registered with ClinicalTrials.gov (NCT0555837). Parents provided informed consent before participation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All participants provided consent to participate including that their data would be published but with identifying information.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Author JD: Consultancy for Marinus, Ultragenyx, Acadia, Avexis, Orion, Takeda, Neurogene, Taysha and Neurocrine. Clinical Trials with Anavex and Newron. Consulting\/Advisory Board member for SCN2A Australia. All remuneration has been made to her department. Author JK: Consultancy for Taysha. All remuneration has been made to her department. Author HL: Consultancy for Marinus, Acadia, Avexis, Orion, Neurogene and Taysha. Clinical Trials with Anavex and Newron. All remuneration has been made to her department. Author EM: Site PI for industry sponsored trials of SK Life, Takeda, Epygenix, Ionis, UCB pharma (Zogenix), and Acadia Pharmaceuticals. Grant funding from NIH, State of Pennsylvania and IRSF, RSRT, and LouLou foundation. Consulting\/Advisory Board member for Acadia Pharmacueticals, Stoke, and Taysha therapeutics. Author TB: Research funding from GRIN2B Foundation, the International Foundation for CDKL5 Research, Loulou Foundation, the National Institutes of Health, and Simons Foundation. Consultancy for Alcyone, AveXis, GRIN Therapeutics, GW Pharmaceuticals, the International Rett Syndrome Foundation, Marinus Pharmaceuticals, Neurogene, Ovid Therapeutics, and Takeda Pharmaceutical Company Limited. Clinical trials with Acadia Pharmaceuticals Inc., GW Pharmaceuticals, Ionis, Marinus Pharmaceuticals, Neurogene, Ovid Therapeutics, and Rett Syndrome Research Trust. All remuneration has been made to his department. Author SD: Consulted for Biomarin, Neurogene, Marinus, Tysha, Ultragenyx, UCB, Capsida, Encoded, Longboard, Mahzi therapeutics, and Ovid Therapeutics. Funding from NIH, Project 8P and Mila\u2019s Miracle Foundation. Advisory board member for non-profit foundations Rare X, SLC6A1 Connect, Project 8P, Ring14 USA, FamilieSCN2A and N of 1 Collaborative. None of the other authors have any declarations of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6"}}